Biocartis Group NV reconfirmed production guidance of 2021. For the period, the company expects Commercial cartridge volume: Targeting a year-over-year growth of 40%-60% or commercial cartridge volumes in the range of 320k-370k. The high-end of the range will only be delivered in case of consistent strong demand for the Idylla™ SARS-CoV-2 Test or its successor the Idylla™ SARS-CoV-2 Panel at attractive average selling prices throughout 2021. Installed base: Targeting 300-350 new Idylla™ instrument placements.